A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer
Clinical trial NCT05629949 · COMPLETED
Trial details
- NCT number
- NCT05629949
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-04-29
- Primary completion
- 2022-12-31
- Enrollment
- 474
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.